LQDA
Liquidia Corporation Common StockData: 2026-09-11
Quick Stats
Sep 11, 202670.4
AI Score
STRONG BUY0.55
Volume Ratio
Nov 02, 2026
Next Earnings
15
+ve Days (30d)
15
-ve Days (30d)
LQDA Price vs Max Options Open Interest
How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.
LQDA Max Change In Options Open Interest
How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.
LQDA Options - Sort by Max open Interest (near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LQDA Daily Out of Money Options - Sort by Max open Interest (near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LQDA Daily In the Money Options - Sort by Max open Interest (near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LQDA Most Active Options by Volume(near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
LQDA Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Volume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
LQDA Stock Summary
Last updated Sep 11, 2026
LQDA is currently trading at $66.74, positioned above its 200-day moving average of $52.13, indicating a long-term uptrend. The stock has a 52-week range of $21.145 to $93.61.
Technical Analysis: The 50-day moving average stands at $77.67, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 38.072, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.061, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates LQDA at 70.4/100 with a STRONG BUY recommendation.
LQDA (Liquidia Corporation Common Stock) Indicators
Last updated Sep 11, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 38.072 |
| CMF (20) | -0.061 |
| ROC (10) | -4.575 |
| ADX (14) | 26.718 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -3.032 |
| AROONOSC (14) | -35.714 |
| WILLAMS %R (14) | -90.818 |
| MFI (14) | 50.309 |
LQDA Candlestick Patterns
Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.
| Date | Pattern | Signal | 5-Day Hit Rate | Edge vs Baseline | Sample |
|---|---|---|---|---|---|
| Sep 11 | Three Inside Down (contrarian — textbook says the opposite) | Bullish | 56.9% | +3.9 pts | 8868 |
| Aug 31 | Thrusting Line | Bearish | 50.0% | +3.0 pts | 9556 |
| Aug 28 | Marubozu (bearish) (contrarian — textbook says the opposite) | Bullish | 56.2% | +3.2 pts | 30540 |
These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.
Liquidia Corporation Common Stock is above the 200 Day SMA but below the 50 Day SMA — long-term uptrend intact but under near-term pressure (Mixed).
LQDA Moving Averages Analysis
Liquidia Corporation Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Sep 11, 2026
LQDA (Liquidia Corporation Common Stock) Simple Moving Averages
Moving Averages are last updated Sep 11, 2026
| Days | MA |
|---|---|
| 10 | 68.11 |
| 20 | 70.23 |
| 30 | 75.32 |
| 50 | 77.67 |
| 100 | 67.83 |
| 200 | 52.13 |
LQDA Fundamental Analysis
| P/E (Forward) | 10.7875 |
| P/E (Trailing) | 49.1667 |
| Market Cap ($) | 6.1 billion |
| Earnings/Share ($) | 1.38 |
| Net Profit Margin (%) | 0.3074 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 3.22 |
| EPS Estimate Next Year ($) | 5.65 |
| WallStreet Target Price ($) | 107.75 |
| Most Recent Quarter |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.